Community

Advertising Opportunities

 Biotechnology Europe Programs

 Resources

Biotechnology Europe Community

Feedback

Contact

Biotechnology Europe Advantages

Advertising Opportunities on Biotechnology Europe

Sponsorship Opportunities on Biotechnology Europe

 

Post a Job on Biotechnology Europe

Post a Company Profile on Biotechnology Europe

Post a News on Biotechnology Europe

Post an Event on Biotechnology Europe

Post a Product on Biotechnology Europe

Post a Publication on Biotechnology Europe

Post a Technology on Biotechnology Europe

Post a Resume on Biotechnology Europe  

Terms of Business

Imprint

Privacy Policy

FAQ

Subscribe Newsletter

 

BIOTECHNOLOGY EUROPE-TURKEY OUT LICENSING

   

 


 
 

   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 
   
   
   
   
   
   
   
   
   
   
 
 
 
 

Offer Summary

Using a lamellar structure as a delivery system, the Sulidin® Nimesulide LPS gel provides enhanced percutaneous penetration of Nimesulide and reduced yellow staining on the skin. LPS Technology worldwide patents are pending.

Mechanism of Action

The anti-inflammatory potency of nimesulide is similar to or greater than indomethacin, diclofenac, piroxicam and ibuprofen. Its analgesic activity is similar to that of ibuprofen.

Full Description

The Lamellar Penetration System (LPS) is based on the concept that the lamellar structure, which lies within the interstitial spaces of the skin, has an affinity to similar structures. Therefore, using a lamellar structure as a delivery system facilitates the penetration of soluble active drug substances into the skin layers. The Embil formulation delivers a soluble form of nimesulide into the skin using this technology. Additionally, the lamellar hydrophobic structure protects against the direct staining of the hydrophobic phase that contains the soluble drug. Therapeutic indications: Sulidin® nimesulide LPS Gel (Embil) is indicated for the topical treatment of a variety of conditions characterized by pain, inflammation and stiffness, such as osteoarthritis, rheumatoid arthritis, periarthritis, post traumatic or acute musculoskeletal disorders including tendonitis, tenosynovitis, bursitis, sprains, strains and lower back pain, as well as sports injuries. Sulidin® Nimesulide Lamellar penetration System (LPS) gel contains 1% (w/w) of nimesulide, a Cox-2 selective non steroidal anti-inflammatory drug (NSAID) of the sulfoanilide class. The anti-inflammatory potency of nimesulide is similar to or greater than that of indomethacin, diclofenac, piroxicam and ibuprofen in animal models. Its analgesic activity is similar to that of ibuprofen and less than that of indomethacin in rats and mice.

Development status

Registred

Patient registration

 

PCT/IB99/01460 "Nimesulide containing topical pharmaceutical compositions".

Approved Country and Number:

USA: 6,818,671; EP Countries: 1105114; China: ZL99811909.1; Turkey: TR 2001 00455B; Singapore: 2001 879-6; New Zealand: 510165; South Africa: 2001 1689; Eurasia*: 2001 00226; Australia: 756007; Czech Republic: 295601; Israel: 141365 *Eurasian Countries: Turkmenistan, Azerbaijan, Moldova, Armenia, Bellarus, Russian Federation, Kazakhstan, Kyrgyzstan, Tajikistan

 

Type of business relationship sought

 

Co-development for worldwide licensing. Outright purchase of worldwide patent rights also possible

 

Licensing contact

 

Dr Koral Embil
Vice President
Research and Development

 

 

 

 I back I top I  

                                                                

office@biotechnology-europe.com I website@biotechnology-europe.com I service@biotechnology-europe.com

 


 

Advertising Opportunities on Biotechnology Europe

Sponsorship Opportunities on Biotechnology Europe

About Biotechnology Europe

Post a Job on Biotechnology Europe

Post a Company Profile on Biotechnology Europe

Post a News on Biotechnology Europe

Post an Event on Biotechnology Europe

Post a Product on Biotechnology Europe

Post a Publication on Biotechnology Europe

Post a Technology on Biotechnology Europe

Post a Resume on Biotechnology Europe


 

Biotechnology Europe Your Partner in Bioscience and Business

  Central Internet Platform and Service Company For The Life Sciences in Europe

Imprint I Site map I Privacy Policy I Contact us I About us I Copyright BIOTECHNOLOGY WORLD  All rights reserved